Results from lidERA trial show a significant improvement in disease-free survival with the novel SERD giredestrant in HR+/HER2- early stage breast cancer fondazionebonadonna.org/en/capivaser... #FondazioneGianniBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social

In a phase 3 trial the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved clinical outcome in patients with advanced head and neck cancer fondazionebonadonna.org/en/neoadjuva... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Adjiuvant abemaciclib added to endocrine therapy improves overall survival in patients with HR+/HER2- high risk early breast cancer fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Results from TUXEDO-3 phase 2 trial show a promising clinical activity for the novel antibody-drug conjugate patritumab deruxtecan in breast cancer patients with acrive brain metastases fondazionebonadonna.org/en/patrituma... #FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social

A new study identifies 7 tumor microenvironment types and shows how they can shape therapeutic response, recurrence and metastases development in breast cancer fondazionebonadonna.org/en/the-relev... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social #Bianchini #Criscitiello

A lot of advances have emerged from the Joint International Conference 2025 Innovation in Oncology organized by FGB with Prada Group supporting partner, by Fondazione Michelangelo and by European School of Oncology fondazionebonadonna.org/en/from-new-... #FondazioneGianniBonadonna #CancerResearch

The Godard Cinema of Fondazione Prada hosted today the opening press conference of the “Joint International Conference 2025”. The event is organized by FGB with the support of #PradaGroup #FondazioneMichelangelo and @ESOncology . fondazionebonadonna.org/wp-content/u... #CancerResearch #Oncology

mRNA vaccines targeting non-tumor-related antigens are potent immune modulators capable of sensitizing tumors to immune checkpoint blockade fondazionebonadonna.org/en/sars-cov-... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Capivasertib added to abiraterone with androgen deprivation therapy increases progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer fondazionebonadonna.org/en/capivaser... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Final overall survival data from SOLTI-1303-PATRICIA trial highlight the relevance of gene expression profiling in HER2+ breast cancer, validating the potential of non-chemotherapy approaches in selected patients fondazionemichelangelo.org/it/notizie-e... #FondazioneMichelangelo #CancerResearch

Adding radiotherapy to immunotherapy can have systemic immunomodulatory and antitumor effects and may be a way to overcome immunotherapy resistance in non-small cell lung cancer fondazionebonadonna.org/en/pembroliz... #FondazioneBonadonna #Oncology @mauriziocallari.bsky.social

A phase 2 study with the antibody-drug conjugate patritumab deruxtecan showed promising activity and manageable tolerability in patients with HR+/HER2− metastatic breast cancer fondazionebonadonna.org/en/patrituma... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Analysis of the NeoTRIP trial showed that tumor-specific MHC-II expression is associated with improved response to neoadjuvant chemo-immunotherapy in early triple negative breast cancer fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #CancerResearch @mauriziocallari.bsky.social

Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, shows a predictable safety profile and a promising antitumor activity in metastatic colorectal cancer fondazionebonadonna.org/en/the-antib... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Camizestrant in association with abemaciclib, palbociclib or ribociclib shows a well-tolerated safety profile and encouraging clinical activity in heavily pretreated advanced breast cancer fondazionebonadonna.org/en/camizestr... #Oncology #CancerResearch @mauriziocallari.bsky.social

Phost’in Therapeutics and Fondazione Gianni Bonadonna to present first clinical data on PhOx430, a First-In-Class GnT-V inhibitor, at @myesmo.bsky.social 2025. Press release fondazionebonadonna.org/wp-content/u... #PhostInTherapeutics #FondazioneBonadonna #therapeuticinnovation #CancerResearch

Respiratory viral infections can lead to loss of the pro-dormancy phenotype in disseminated #BreastCancer cells in the lung, causing proliferation and expansion of carcinoma cells within days fondazionebonadonna.org/en/metastati... #FondazioneBonadonna #Oncology @mauriziocallari.bsky.social

The ATRACTIB phase 2 trial shows clinical benefit with a combination of atezolizumab, paclitaxel and bevacizumab as first-line treatment in advanced triple-negative breast cancer fondazionebonadonna.org/en/atezolizu... #FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social

A dual HER2-targeted blockade with neoadjuvant pyrotinib and ARX788, a new antibody-drug conjugate, as a promising strategy in early or locally advanced HER2-positive breast cancer fondazionebonadonna.org/en/pyrotinib... #FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social

Milan to host the Joint Conference 2025 on New Drugs and the Impact of AI in Oncology, organized by FGB with the Prada Group as supporting partner, Fondazione Michelangelo and @ESOncology . Press Release fondazionebonadonna.org/area-press/ #FondazioneGianniBonadonna #FondazioneMichelangelo

SERENA-6 trial shows a longer progression-free survival with camizestrant added to a CDK4/6 inhibitor in advanced breast cancer with an ESR-1 mutation emerged during treatment fondazionemichelangelo.org/news-update/... #FondazioneBonadonna #FondazioneMichelangelo #CancerResearch #Oncology

MATTERHORN trial results show a significantly better event-free survival with perioperative durvalumab added to chemotherapy in resectable gastric or gastroesophageal junction adenocarcinoma fondazionebonadonna.org/en/periopera... #FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social

Final results from the IMpassion031 trial confirm that adding atezolizumab to neoadjuvant chemotherapy significantly improved clinical outcomes and cleared ctDNA at surgery fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #CancerResearch #Oncology

A phase 3 study shows clinical benefit for tarlatamab as second-line treatment after chemotherapy in patients with small-cell lung cancer fondazionebonadonna.org/en/longer-su... #fondazionemichelangelo #oncology #CancerResearch @mauriziocallari.bsky.social

In ER-positive, HER2-negative advanced breast cancer vepdegestrant led to significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations www.fondazionemichelangelo.org/news-update/... #fondazionemichelangelo #oncology #CancerResearch

Trastuzumab deruxtecan led to significantly longer overall survival than ramucirumab plus paclitaxel among patients with HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma fondazionebonadonna.org/en/trastuzum... #FondazioneBonadonna #Oncology #CancerResearch

“Online the Scientific Programme of the FGB-FM-ESO Joint International Conference 2025 “INNOVATION IN ONCOLOGY: New Drugs and the Impact of Artificial Intelligence”. Read more and register online at www.eso.net/en/what-we-d...

Adjuvant cemiplimab led to to longer disease-free survival than placebo in cutaneous squamous-cell carcinoma with a high risk for recurrence fondazionebonadonna.org/en/cemiplima... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Addition of pembrolizumab to enzalutamide and androgen deprivation therapy is not effective in metastatic hormone-sensitive prostate cancer fondazionebonadonna.org/en/pembroliz... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Sunday July 20th is the deadline for submitting applications for the “Fellowship Gianni Bonadonna” ed 25 – Read more fondazionebonadonna.org/en/fellowshi... Il 20 luglio scadono i termini per inviare la candidature per la “Fellowship Gianni Bonadonna” 25 - Leggi fondazionebonadonna.org/fellowship/

Inavosilib plus palbociclib-fulvestrant led to a significant survival benefit versus placebo plus palbociclib-fulvestrant in PIK3CA-mutated advanced breast cancer fondazionebonadonna.org/en/inavosili... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

A first-line treatment with alectinib plus bevacizumab show efficacy and safety in ALK-rearranged non-small cell lung cancer fondazionebonadonna.org/en/alectinib... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Nivolumab plus low-dose ipilimumab shows good response rate and a clinical benefit in hypermutated HER2-negative metastatic breast cancer fondazionebonadonna.org/en/nivolumab... #fondazionebonadonna #oncology #CancerResearch @mauriziocallari.bsky.social

Trastuzumab rezetecan showed robust activity with a tolerable safety profile in a neoadjuvant setting in HER2-positive breast cancer fondazionebonadonna.org/trastuzumab-... #fondazionebonadonna #Oncology #breastcancer @mauriziocallari.bsky.social

First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low, tissue or blood tumor mutational burden fondazionebonadonna.org/en/durvaluma... #fondazionebonadonna #CancerResearch @mauriziocallari.bsky.social

Clinically meaningful activity and manageable safety for trastuzumab rezetecan in advanced, previously treated HER2mutant non small-cell lung cancer fondazionebonadonna.org/en/trastuzum... #fondazionebonadonna #oncology #CancerResearch @mauriziocallari.bsky.social

Avoidance of breast surgery after neoadjuvant systemic therapy may be feasible in selected invasive breast cancer patients fondazionemichelangelo.org/news-update/... #fondazionemichelangelo #CancerResearch #Oncology @mauriziocallari.bsky.social

Fondazione Gianni Bonadonna, with #PradaGroup as supporting partner, announces the edition 2025 of the post-doctoral Fellowship Program in collaboration with the #ESOncology Applications open from June 3rd until July 20th. #fondazionebonadonna #fellowship fondazionebonadonna.org/en/a-new-edi...

Afami-cel showed durable responses in heavily pretreated patients with sarcoma, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy fondazionebonadonna.org/en/afamitres... #fondazionebonadonna #oncology #CancerResearch @mauriziocallari.bsky.social

Sacituzumab tirumotecan showed improvements in progression-free survival compared to chemotherapy, with a manageable safety profile, in metastatic triple-negative breast cancer fondazionebonadonna.org/en/sacituzum... #FondazioneBonadonna #oncology #CancerResearch @mauriziocallari.bsky.social

Whole genome sequencing-powered ctDNA sequencing improves detection at baseline and follow-up helping to identify early breast cancer patients at high risk of relapse www.fondazionemichelangelo.org/news-update/... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

A new phase II trial shows a clinical potential for regorafenib plus avelumab in gastroenteropancreatic neuroendocrine neoplasms www.nature.com/articles/s43... #fondazionebonadonna #oncology #CancerResearch @mauriziocallari.bsky.social

The longest follow-up for immune checkpoint inhibitor plus tyrosine kinase inhibitor combination treatment in advanced renal cell carcinoma shows efficacy benefits and durable response fondazionebonadonna.org/en/avelumab-... #Oncology #CancerResearch #FondazioneGianniBonadonna

By analyzing tumor methylome profiles, a new study defines two epigenetic triple-negative breast cancer subtypes with different transcriptional patterns and tumor microenvironment features fondazionebonadonna.org/en/dna-methy... #FondazioneBonadonna #Oncology #CancerResearch

From #immunotherapy (IO) failures to new strategies & biotech innovations in metastatic TNBC, to IO timing, chemo backbones, & novel approaches in the early stage. All this & more in our latest review on immune checkpoint inhibitors in #TNBC. shorturl.at/izpbe @dfcibreastonc.bsky.social

A new study validates the survival association of the clonal expression biomarker ORACLE in patients with lung adenocarcinoma fondazionebonadonna.org/en/the-valid... #FondazioneBonadonna #Oncology @mauriziocallari.bsky.social

In a new phase 3 trial ivonescimab significantly improved progression-free survival compared with pembrolizumab in previously treated PD-L1- positive non-small cell lung cancer fondazionebonadonna.org/en/ivonescim... #FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social

Addition of tiragolumab might improve clinical activity of a combination with atezolizumab plus bevacizumab in unresectable, locally advanced or metastatic hepatocellular carcinoma fondazionebonadonna.org/en/tiragolum... #FondazioneBonadonna #BreastCancer #Oncology @mauriziocallari.bsky.social

A combination of ibrutinib–venetoclax significantly improved progression-free survival compared with ibrutinib–placebo in patients with relapsed or refractory mantle cell lymphoma fondazionebonadonna.org/en/ibrutinib... #fondazionebonadonna #oncology #CancerResearch

Analysis of molecular data from the NA-PHER2 trial, led from Michelangelo researchers identified new biomarkers predictive of response in HER2+/ER+ breast cancer patients receiving targeted treatments www.fondazionemichelangelo.org/2025/03/10/n...